Drug interactions of Capmatinib

1.Effect of Other Drugs on Capmatinib

1.1Strong CYP3A Inhibitors

Coadministration of Capmatinib with a strong CYP3A inhibitor increased capmatinib exposure, which may increase the  incidence and severity of adverse reactions of Capmatinib. Closely monitor patients  for adverse reactions during coadministration of Capmatinib with strong CYP3A inhibitors.

1.2Strong and Moderate CYP3A Inducers

Coadministration of Capmatinib with a strong CYP3A inducer decreased capmatinib exposure. Coadministration of Capmatinib with a moderate CYP3A inducer may also decrease capmatinib exposure. Decreases in capmatinib exposure  may decrease Capmatinib anti-tumor activity. Avoid coadministration of Capmatinib with strong and moderate CYP3A inducers. 

2.Effect of Capmatinib on Other Drugs

2.1CYP1A2 Substrates

Coadministration of Capmatinib increased the exposure of a CYP1A2 substrate, which may increase the adverse reactions of these substrates. If coadministration is unavoidable between Capmatinib and CYP1A2 substrates where minimal concentration changes may lead to serious adverse reactions, decrease the CYP1A2 substrate dosage in accordance with the approved prescribing information.

2.2P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP) Substrates

Coadministration of Capmatinib increased the exposure of a P-gp substrate and a BCRP substrate, which may increase the adverse reactions of these substrates. If coadministration is unavoidable between Capmatinib and P-gp or BCRP substrates where minimal concentration changes may lead to serious adverse reactions, decrease the P-gp or BCRP substrate dosage in accordance with the approved prescribing information.

2.3MATE1 and MATE2K Substrates

Coadministration of Capmatinib may increase the exposure of MATE1 and MATE2K substrates, which may increase the adverse reactions of these substrates. If coadministration is unavoidable between Capmatinib and MATE1 or MATE2K substrates where minimal concentration changes may lead to serious adverse reactions, decrease the MATE1 or MATE2K substrate dosage in accordance with the approved prescribing information.

from FDA,2023.03